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Abstract
Background: Molecular diagnostics can resolve locus heterogeneity underlying clinical phenotypes that may
otherwise be co-assigned as a specific syndrome based on shared clinical features, and can associate
phenotypically diverse diseases to a single locus through allelic affinity. Here we describe an apparently novel
syndrome, likely caused by de novo truncating mutations in ASXL3, which shares characteristics with Bohring-Opitz
syndrome, a disease associated with de novo truncating mutations in ASXL1.
Methods: We used whole-genome and whole-exome sequencing to interrogate the genomes of four subjects
with an undiagnosed syndrome.
Results: Using genome-wide sequencing, we identified heterozygous, de novo truncating mutations in ASXL3, a
transcriptional repressor related to ASXL1, in four unrelated probands. We found that these probands shared similar
phenotypes, including severe feeding difficulties, failure to thrive, and neurologic abnormalities with significant
developmental delay. Further, they showed less phenotypic overlap with patients who had de novo truncating
mutations in ASXL1.
Conclusion: We have identified truncating mutations in ASXL3 as the likely cause of a novel syndrome with
phenotypic overlap with Bohring-Opitz syndrome.
Background
Widespread use of high-throughput sequencing has
helped elucidate the genetic heterogeneity underlying
phenotypically similar syndromes. Bohring-Opitz syn-
drome (BOS; MIM 605039] is characterized by distinct
craniofacial features and posture, severe intellectual dis-
ability, feeding problems, small size at birth, and failure
to thrive [1], but shares some of these features with other
syndromes. Recently, de novo truncating mutations in
ASXL1 have been shown to account for approximatly
50% of cases with BOS [2];we initially and independently
identified two individuals with de novo truncation muta-
tions in a related gene, ASXL3. Subsequent interrogation
of a small cohort identified two additional individuals
with similar mutations. In all four families, the affected
children had BOS-like features, but had no specific
recognizable syndromic diagnosis. Subjects 1, 2, and 4
had similar clinical histories, including severe psychomo-
tor retardation, feeding problems, severe post-natal
growth retardation, arched eyebrows, anteverted nares,
and ulnar deviation of the hands (Table 1, Figure 1),
which are features partially shared with Cornelia de
Lange Syndrome (CdLS) and BOS, but they did not have
the trigonocephaly that is characteristic of BOS. Subject
3 also displayed anteverted nares, but had less severe psy-
chomotor retardation and had normal growth. At 5 years
of age, she has intellectual disability and does not speak.
Magnetic resonance imaging data, which was only
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Table 1 Parental age at conception and gestation, and phenotypes of affected subjects and of typical BOS.
Subject 1 Subject 2 Subject 3 Subject 4 BOS
Parental age,
years
45/44 30/29 24/29 26/26
Gestation 38 2/7 weeks; poor fetal
growth; polyhydramnios
39 weeks, breech birth 38 weeks, C-section 40 weeks, spontaneous vaginal delivery
Size at birth ~1% ~1% 40% Weight 50%; length 25 to 50% Approximately 1%
Gastrointestinal Gastric tube feeds for 8
months, gastro-esophageal
reflux
Gastric tube feeds first month No obvious difficulties Difficulty latching on from birth; poor
oral feeding resulted in admission at
age 8 weeks for failure to thrive; gastro-
esophageal reflux; Nissen fundoplication
and G-tube placed
Feeding difficulties
Craniofacial
features
Arched, thin eyebrows; high,
narrow palate; low, posteriorly
rotated ears; microcephaly;
anteverted nares, large
fontanels; retroganthia; long
eyelashes
Arched eyebrows; high, narrow palate;
low, posteriorly rotated ears;
microcephaly; anteverted nares;
hypertelorism; short nose; gingival
hyperplasia; sparse hair; scaly scalp;
hyperopia
Prominent forehead/frontal
bossing; short nose with
anteverted nares
Prominent forehead; arched eyebrows;
hypoplastic alae nasi; low-set ears; high
and narrow palate
High, narrow palate; low-set,
posteriorly rotated ears;
microcephaly; trignocephaly;
anteverted nares; prominent eyes;
upslanting palpebral fissures;
depressed nasal bridge
Somatic
features
Ulnar deviation of hands at
rest; deep palmar and plantar
creases; hypertonia; bladder
dysfunction; testes normally
descended
Ulnar deviation of hands; deep palmar
creases; hypotonia; clenched hands;
undescended testes
Mild global hypotonia Exotropia; hirsutism; supranumerary
nipple; low truncal tone with
abnormally fluctuating tone in limbs; no
clonus; mild ulnar deviation of the hands;
deep palmar creases and clenching of
hands, less prominent over time
High myopia; hirsutism; ‘BOS’
posture: exorotation and/or
adduction of the shoulders;
flexion at the elbows; flexion at
the wrists; and ulnar deviation of
the hands
and/or fingers at the MCP joints
Post-natal
growth &
development
Weight, length & OFC all -4.5
to -5.0 SD; psychomotor delay.
Died aged 9 months.
Size < 1%;a severe psychomotor delay Normal growth; global
developmental delay with
intellectual disability
Age 41.5 months:
OFC < 2nd%; 50th % for age 1 year;
Length, weight 10 to 25 th percentile;
unable to sit independently; non-verbal;
no sign language; mostly G-tube fed
Growth retardationa; psychomotor
delay; high rate of infant mortality
Brain imaging
results
Global mild white-matter volume loss
with normal myelination; secondary
brainstem hypoplasia; hypoplasia/
dysplasia of bilateral cerebellar tonsils;
mild inferior vermian hypoplasia;
normal MR spectroscopy
Enlarged ventricles, agenesis of
corpus callosum, Dandy-Walker
malformation, delayed
myelination,
and cortical atrophy
Laboratory
testing with
non-diagnostic
results
NIPBL sequencing (Cornelia
de Lange)
aCGH; urine oligosaccharide;
sequencing panel for Noonan, Prader-
Willi, cardiofaciocutaneous, and Costello
syndromes; thin-layer chromatography
for fucosidosis, mannosidosis,
aspartylglucosaminuria, GM1- and GM2-
gangliosidosis, galactosialidosis,
Schindler and Pompe disease; [AU What
does ‘M’ stand for here? Are these
Schindler disease and Pompe disease?
Ms have been removed ]
electrophoresis for congenital disorders
of glycosylation
SNP aCGH; methylation for
Angelman; plasma and urine
creatine and
guanidinoacetate; urine
purine and polyol panels;
plasma homocysteine
46, XX; SNP aCGH;
Sequencing panel for congenital
disorders of glycosylation;
N-glycans; methylation for Angelman
syndrome; MECP2 sequencing; muscle
biopsy gave normal electron and light
microscopy results;
urinary organic acids; plasma amino
acids; CPK
aCGH, array-comparative genomic hybridizationl BOS, Boehring-Opitz; CPK, creatine phosphokinase; G-tube; gastric tube; MCP, metacarpophalangeal; MECP, methyl CpG binding protein; MR, magnetic resonance;
OFC, occipitofrontal circumference; SD, standard deviation; SNP, single-nucleotide polymorphism.
Features shared by at least two subjects and BOS are in italics.
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Figure 1 Clinical presentation of four subjects. (A, B) Subject 2 aged (A) 1 month and (B) 38.5 months. Note the high forehead, low-set ears,
thin arched eyebrows and anteverted nares. (C) Subject 3, aged 5 years, Note high and broad forehead, periorbital fullness, and anteverted
nares. (D-F) Subject 4, aged 41.5 months, showing prominent tall forehead, arched eyebrows with subtle synophrys and periorbital fullness,
prominent columella with hypoplastic alae nasi, thin upper lip, and borderline low-set ears. Note that none of the patients has trigonocephaly or
prominent metopic ridge, as seen in Boehring-Opitz syndrome. Images were not available for subject 1.
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available for subject 4, showed cerebral volume loss over
time, a feature seen in some cases of BOS (see Additional
file 1, Figure S1). In the exome data of any of the sub-
jects, no rare variants were found in the genes known to
cause BOS and CdLS.
Methods
Ethics approval
The study was approved by the Baylor Institutional
Review Board (IRB), by the appropriate ethical commit-
tee at the MPIMG, and informed consent was obtained
from the guardians of all subjects.
DNA
DNA from subjects and their parents was obtained
under written informed consent, provided by their par-
ents or legal guardians, for participation in the study.
The parents or legal guardians consented to publication
of their children’s images and clinical details. The study
was approved by the Institutional Review Board at Bay-
lor College of Medicine for all sequencing conducted at
the Baylor College of Medicine Human Genome
Sequencing Center (BCM-HGSC). This study was con-
ducted in accordance with the Helsinki declaration.
Library construction
Library construction was carried out at BCM-HGSC. After
determining DNA concentration and integrity, high mole-
cular weight double-stranded genomic DNA samples were
constructed into pre-capture libraries (PairEnd; Illumina
Inc., San Diego, CA, USA) in accordance with the manu-
facturer’s protocol with some modification. Briefly, 1 μg
genomic DNA in a volume of 100 μl was sheared into
fragments of approximately 300 bp in a 96-well plate with
an automatic processor(E210 system; Covaris, Inc.
Woburn, MA, USA), using the 10% duty cycle setting,
with an intensity of 4, and 200 cycles/burst for 120 sec-
onds. Fragment size was evaluated using a 2.2% gel cas-
sette (FlashGel DNA Cassette; catalog No. 57023; Lonza
Group, Boston, MA, USA). The fragmented DNA was
end-repaired in 90 μl total reaction volume containing
sheared DNA, 9 μl 10× buffer, 5 μl enzyme mix (END
Repair Enzyme Mix; New England Biolabs, Beverly, MA,
USA) and H2O (NEBNext End Repair Module; catalog no.
E6050L; New England Biolabs) and then incubated at 20°C
for 30 minutes. A-tailing was performed in a total reaction
volume of 60 μl containing end-repaired DNA, 6 μl 10×
buffer, 3 μl Klenow Fragment (NEBNext dA-Tailing Mod-
ule; catalog no. E6053L; New England Biolabs), and H2O,
followed by incubation at 37°C for 30 minutes. Illumina
multiplex adapter ligation (NEBNext Quick Ligation Mod-
ule catalog no. E6056L;; New England Biolabs) was per-
formed in a total reaction volume of 90 μl containing
18 μl 5× buffer, 5 μl ligase, 0.5 μl 100 μmol/l adaptor, and
H2O at room temperature for 30 minutes. After ligation,
PCR with primer PE 1.0(Illumina) and modified barcode
primers (manuscript in preparation) was performed in
170 μl reactions containing 85 2× PCR master mix (Phu-
sion High-Fidelity; New England Biolabs), adaptor-ligated
DNA, 1.75 μl of 50 μM each primer and H2O. The stan-
dard thermocycling for PCR was 5 minutes at 95°C for the
initial denaturation followed by 6 to 10 cycles of 15 sec-
onds at 95°C, 15 seconds at 60°C and 30 seconds at 72°C,
with a final extension for 5 minutes at 72°C. Magnetic
beads (Agencourt® XP® Beads; catalog no. A63882; Beck-
man Coulter Genomics, Inc., Danvers, MA, USA) were
used to purify DNA after each enzymatic reaction. After
bead purification, PCR product quantification and size dis-
tribution was determined using a DNA assay (GX 1K/
12K/High Sensitivity Assay Labchip; catalog no. 760517;
Caliper, Hopkinton, MA, USA).
Exon capture
At BCM, 1 μg of Illumina paired-end pre-capture library
DNA was hybridized to a custom capture reagent designed
at the HGSC and constructed by Roche/NimbleGen
(reference no. 9999042355 Madison, WI, USA). This
reagent targets the coding regions of genes reported by
CCDS, ENSEMBL, UCSC, GenCode, VEGA, and RefSeq.
It also targets micro RNA (miRNA) and small nucleolar
RNA detailed by UCSC, predicted miRNA binding sites,
and 1000 Sanger-predicted miRNAs. This design is avail-
able upon request. Hybridization was conducted in accor-
dance with the manufacturer’s protocol, (NimbleGen,
Madison, WI, USA) with minor revisions. Specifically,
three hybridization-enhancing oligos, IHE1, IHE2, and
IHE3, (manuscript in preparation) replaced oligos HE1.1
and HE2.1, and post-capture LM-PCR was performed
using 14 cycles. Capture libraries were quantified (GX 1K/
12K/High Sensitivity Assay Labchip; catalog no. 760517;
Caliper). The efficiency of the capture was evaluated by
performing a quantitative (q)PCR-based quality check on
the built-in controls (qPCR SYBR Green assays; Applied
Biosystems, Foster City, MA, USA). Four standardized
oligo sets, RUNX2, PRKG1, SMG1, and NLK, were used
as internal quality controls. The enrichment of the capture
libraries was estimated to range from seven-fold to nine-
fold over background.
Whole-exome sequencing
Whole-exome sequencing was carried out at the Max
Planck Institut für molekulare Genetik (MPIMG).
Whole-exome sequencing libraries were prepared (Sure-
Select XT Target Enrichment System for Illumina
Paired-End Sequencing Library; Agilent Technologies
Inc., Wilmington, DE, USA). Genomic DNA samples
were used to generate Illumina PairEnd pre-capture
libraries in accordance with the manufacturer’s protocol
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(Agilent Technologies). After determining concentration
and quality, 3 μg genomic DNA was sheared into frag-
ments with an average length of 150 and 200 bp using a
Covaris S2 system (Covaris, Inc. Woburn, MA). The set-
ting was 10% duty cycle, with an intensity of 5, and 200
cycles/burst, for 360 seconds. After purification using
magnetic beads (Agencourt AMPure XP; catalog No.
A63882; Beckman Coulter Genomics), fragment size was
checked using a bioanalyzer (2100; Agilent). The frag-
mented DNA was end-repaired in 100 μl total reaction
volume containing 48 μl sheared DNA, 10 μl 10× buffer,
1.6 μl dNTP, 1 μl T4 DNA polymerase, 2 μl Klenow
DNA polymerase and 2.2 μl T4 polynucleotide kinase,
and then incubated at 20°C for 30 minutes. A-tailing
was performed in a total reaction volume of 50 μl con-
taining end-repaired DNA, 5 μl 10× buffer, 3 μl Klenow
fragment, 1 μl dATP, and 11 μl water, followed by an
incubation at 37°C for 30 minutes. Illumina adapter liga-
tion was performed in a total reaction volume of 50 μl
containing 10ul 5× buffer, 10 μl ligase and 10 μl adaptor
oligo mix at room temperature for 30 minutes. After
ligation, PCR with Illumina PE 1.0 and reverse primer
(SureSelect GA Indexing Pre Capture PCR Reverse Pri-
mer; Agilent Technologies) was performed in 50 μl reac-
tions containing 10 μl 5× buffer (Herculase II Rxn;
Agilent Technologies), adaptor-ligated DNA, 1.25 μl of
each primer, 0.5 100 mmol/l dNTP mix and 1 μl DNA
polymerase (Herculase II Fusion; Agilent Technologies.
The standard thermocycling for PCR was 2 minutes at
98°C for the initial denaturation, followed by six cycles
of 30 seconds at 98°C, 30 seconds at 65°C, and 60 sec-
onds at 72°C, with a final extension for 10 minutes at
72°C. Magnetic beads (Agencourt® XP® Beads; Beckman
Coulter Genomics; catalog no. A63882) was used to
purify DNA after each enzymatic reaction. After bead
purification, PCR product quantification and size distri-
bution was determined using a bioanalyzer (model 2100;
Agilent Technologies) and Qubit software (University of
Oxford, Oxford, UK), then 500 ng of the Illumina
paired-end pre-capture library DNA was hybridized to
Agilent SureSelect human exome capture probes in
accordance with the manufacturer’s specifications. After
assessing the quality of capture libraries using a bioana-
lyzer (2100; Agilent Technologies), the captured library
was sequenced using a sequencing system (Hi-Seq 2000;
Illumina) in accordance with the manufacturer’s proto-
col. Each library was sequenced in a separate lane in a
101-nucleotide single-end sequencing format.
The whole human genomes were resequenced by a
commercial company (Complete Genomics, Mountain
View, CA, USA) with unchained base reads on self-
assembling DNA nanoarrays [3], and the variants called
by using mated gapped reads [4].
Sequence alignment, variant calling, annotation, and
verification
At BCM, Illumina data was aligned by use of Burrows-
Wheeler Aligner (BWA) software. Variants were called
using ATLAS-SNP v2.0 and the SAMtools program
Pileup. De novo variants were found by in silico subtrac-
tion of the variants discovered in either parent. Variants
were subsequently annotated for effect on the protein,
known minor allele frequencies, and gene function using
AnnoVar and custom in-house developed software.
Candidate variants were verified and segregation exam-
ined using Sanger capillary sequencing.
At MPIMG, the exonic region of human genome was
enriched (SureSelect Human All Exon Kits; Agilent
Technologies), and deep sequenced (HiSeq 2000; Illu-
mina). Raw sequence reads were pre-screened to remove
low-quality reads, and then aligned to the human refer-
ence genome with SOAP (version 2.21). Aligned and
unaligned reads were used to call the single-nucleotide
variants (SNVs) and Indels, respectively. Variant lists
were filtered against the reference databases and ranked
as potential candidates [5].
The primary variant list from Complete Genomics was
filtered and prioritized by an in-house pipeline [5].
De novo mutations in each patient were defined as those
absent from all other members in the family and that
had been flagged as ‘high quality’ and supported by at
least five reads with allele percentage of 0.4 to 0.6.
Candidate variants were verified and segregation tested
using Sanger capillary sequencing.
RNA extraction and reverse transcriptase-PCR
experiments
A cell line from subject 2 was established by Epstein-Barr
virus transformation, in accordance with standard proto-
cols after informed consent. Total RNA was extracted
from patient cells using a commercial kit (RNeasy Plus;
Qiagen Inc., Valencia, CA, USA) in accordance with the
manufacturer’s recommendations. For reverse transcrip-
tion, 1 μg of RNA was used with 10 U of Superscript III
(Invitrogen Corp., Carlsbad, CA, USA), and 150 μmol/l
random hexamers in the presence of ribonuclease inhibi-
tor (RNasin; Promega Corp., Madison, WI, USA) in accor-
dance with the manufacturer’s protocol. Reverse
transcriptase (RT)-PCRs for allele expression analysis of
ASXL3 were carried out using a PCR mix (BIO-X-ACT
Long Mix; Bioline Reagent Ltd, London, UK) and primers
(ASXL3_RTmut_for 5’-AAATGCAGTTGCGGATAAGG-
3’ and ASXL3_RTmut_rev 5’-TGGGGTTCTTCATGA-
GAATTC-3’), located in exons 10 and 11. After initial
denaturation at 94°C for 3 min, cycling conditions were:
40 cycles at 94°C, 55°C and 72°C. Each step was for
45 seconds.
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ASXL3 analysis
Exon data for the gene and prosite regions was
extracted from the ENSEMBL genome browser [6].
Vertebrate conservation was obtained from the UCSC
Genome browser [7], using the vertebrate conserved ele-
ments track (Vertebrate Multiz Alignment & Conserva-
tion (46 Species): Vertebrate Conserved Elements) with
a minimum LOD score of 700. Predicted motifs were
obtained from the eukaryotic linear motif [8] server with
a motif probability cut-off of 0.005. All phosphorylation
events were grouped together. ASXL family similarity
was calculated by BLASTing ASXL1 and ASXL2 amino
acid sequences against ASXL3 using NCBI-BLASTP [9].
Results and discussion
To identify potential causative alleles, genome sequencing
was undertaken in each family we identified (see Addi-
tional file 2, Table S1). For family 1, we interrogated the
exome of both parents and the affected child using a cus-
tom exon-capture reagent, followed by high-throughput
sequencing with the Illumina HiSeq platform. For family
2, we obtained the whole genome sequence of the affected
child, his unaffected sibling, and both parents from Com-
plete Genomics. We also performed exome sequencing in
this family as part of a pilot study to compare the yield of
these methods (see Methods). For families 3 and 4, exome
sequencing was performed on the proband only. After
sequencing, we identified all coding and near-intronic dif-
ferences between the subjects and the human reference
genome (see Methods). By using the unaffected parents as
controls, it was possible to identify de novo mutations in
the affected subject.
In each generation, 70 to 175 de novo point mutations
are expected [10,11], and 0 to 3 of these are anticipated
to cause protein-coding changes [11]. In subject 1, a sin-
gle protein-coding de novo mutation was identified
(chr18, g.31318578C > T, p.Q404X; hg19). In subject 2,
two coding de novo mutations were identified. The first
(chr16, g.75258715G > A, p.R248H) occurred in CTRB1,
and was considered non-pathogenic, as the variant has
been reported in samples analyzed for the Thousand
Genomes project (rs191950160), and is identical to the
orthologous alleles in the chimpanzee and rhesus maca-
que. The second occurred in ASXL3 (chr18, g.31318764C
> T, p.Q466X) and has not been previously reported. In
subject 3, a de novo 4 bp deletion was identified (chr18,
g.31319343_31319346delACAG, p.T659fsX41); this fra-
meshift was predicted to generate a premature termina-
tion codon (TGA) after an additional 41 amino acids. In
subject 4, a de novo 1 bp insertion was identified (chr18,
g. 31318789_insT, p.P474fs); this frameshift mutation
was predicted to generate a premature termination
codon immediately. In all cases, the variant was
interrogated in the affected child and parental DNA
obtained from peripheral blood by Sanger capillary
sequencing. All four de novo ASXL3 mutations generated
stop codons, and were predicted, in silico, to generate a
truncated ASXL3. Further, the mRNAs containing these
premature stop-codon mutations may be degraded by
nonsense-mediated decay (NMD) and thus could repre-
sent loss-of-function alleles. Neither SNV allele occurred
in a CpG dinucleotide; the only known site with an
increased propensity for de novo mutations [10] (see
Additional file 3, Table S2).
In Drosophila, the additional sex combs (Asx) gene is
required to maintain homeotic gene activation and silen-
cing, and in mice, three orthologs (Asxl1, Asxl2, and Axl3)
have been identified. Asxl1 acts on the developmentally
important Hox genes both as a repressor (HoxA4, HoxA7,
and HoxC8) and as an enhancer (HoxC8) [12]; dysregula-
tion of the human HOX genes may account for the devel-
opmental phenotype. Little information is available about
either embryologic or fetal expression of the ASXL gene
family; however, in Drosophila, regulation of the Asx gene
is highly variable and tightly controlled in the first 3 hours
after fertilization [13]. In humans, ASXL3, like ASXL1 and
ASXL2, is a putative polycomb protein and probably acts
as a histone methyltransferase in a complex with other
proteins [14]. ASXL3 is expressed in similar tissues to
ASXL1 including brain, spinal cord, kidney, liver, and bone
marrow, but at a lower level [15] (see Additional file 4,
Figure S2). Within the brain, ASXL1 has much higher
expression in the white matter, whereas ASXL3 has mod-
erately higher expression in the insula, cingulate gyrus,
and amygdala, with approximately similar expression else-
where [16] (see Additional file 5, Figure S3). The high cor-
relation of expression patterns between ASXL1 and ASXL3
may account for some of the shared phenotypic features.
No deleterious ASXL3 mutation was found in a small
cohort of patients with BOS without causative ASXL1
mutation (Hoischen, personal communication), consis-
tent with ASXL3 mutations conveying a phenotype dis-
tinct from BOS. Using large-scale datasets (Thousand
Genomes [17], dbSNP, ESP5400, and Cohorts for Heart
and Aging Research in Genomic Epidemiology [18]) we
identified four other truncating mutations in ASXL3,
which occurred as singletons within each dataset in
reportedly phenotypically normal individuals (Figure 2),
and thus may represent benign variants. Two of these
mutations occur at the extreme 3’ of the gene, and thus
may escape NMD and retain protein activity. One muta-
tion, p.L902X (rs187354298), identified in a single sample
from the Thousand Genomes cohort, occurs more 3’ to,
but within the same penultimate exon as, the two dis-
ease-causing mutations (see Figure 2). More interestingly,
however, a high-quality nonsense mutation (R322X) was
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identified in the exon 9 of the 12-exon ASXL3 gene, and
is anticipated to undergo NMD or may be otherwise
highly deleterious to protein function.
Although all four disease-associated de novo variants
and rs187354298 are predicted to potentially undergo
NMD, it is challenging to reconcile such a hypothesis
with the observed range of phenotypes for nonsense
alleles reported at this locus. However, the current ability
to predict NMD is limited, and it has been shown that
around 75% of mRNA transcripts that are predicted to
undergo NMD escape destruction, and that the nonsense
codon-harboring mRNA is expressed at levels similar to
wild type in lymphoblastoid cells [19]. Furthermore, the
dynamics of mRNA stability and degradation may differ
for cells and tissues undergoing rapid developmental
changes. Parenthetically, we noted an enrichment of
around 50% in gene regions where mRNA would be pre-
dicted to escape NMD, or 3’ gene bias to the predicted
loss-of-function nonsense codon mutations in normal
controls from the Thousand Genomes data [19].
Another distinct interpretation of our observations is
that all ASXL3 disease-causing nonsense-encoding
mRNAs are translated into prematurely terminated pro-
teins, which act in a dominant-negative fashion. In sup-
port of this hypothesis, Sanger sequencing of multiple
cDNA extractions derived from a transformed lympho-
blast cell line from subject 2 showed that both alleles
were expressed (see Additional file 6, Figure S4) although
this does not exclude that some degree of NMD may
occur or reflect what occurred during development.
Further, we observed that in previously reported cases of
BOS known disease-causing nonsense mutations in
ASXL1 [2,20] occur almost entirely within a very limited
region of the protein,. Furthermore, database searches
reveal that truncating mutations, in reportedly
phenotypically normal individuals, can occur both 5’ and
3’ of these mutations, just as we now report for ASXL3
(see Additional file 7, Figure S5). This disease-causing
mutation hotspot falls between two paralogous regions
shared by all ASXL genes (Figure 2) and into a region
unique to ASXL1. Interestingly, the presumptive disease-
causing mutations we describe here occur within an ana-
logous region in ASXL3, within the first half of the penul-
timate exon. Further, disease severity may decrease the
more 3’ the mutation occurs within this region. This
region contains a number of predicted phosphorylation
sites, an evolutionarily conserved region (residues 420 to
470, approximately), and an evolutionarily conserved ser-
ine-rich motif between residues 600 and 800, approxi-
mately. We speculate that disruption of these conserved
regions may result in dysregulation of post-translational
protein modification, resulting in constitutive activation.
Truncating ASXL3 mutations are uncommon, and
their de novo nature makes it even less likely that we
identified these individuals by chance, which highlights
the value of de novo mutation-based methods to find
disease-causing loci. To determine the probability of
observing multiple de novo truncating mutations in
ASXL3, we developed a model [21,22] accounting for
gene size, GC content and de novo rates of SNVs and
small insertion/deletions, and of the probability of those
mutations causing a truncation of the protein. The
probability of developing a de novo nonsense mutation
in ASXL3 is 3.35 × 10-6 per generation, whereas the
probability of developing a de novo coding insertion or
deletion in ASXL3 is approximately 3.91 × 10-6. Thus,
the total probability of observing three additional indivi-
duals with truncating ASXL3 mutation, given the first de
novo observation, is around 4.0 × 10-17. The observation
of four de novo truncating mutations occurring in
2248
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similarity to lowest: red, pink, green, blue, brown). Adapted from UCSC Genome browser, ENSEMBL, eukaryotic linear motif server, and NCBI-
BLASTP.
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association with a sporadic disease that shares similar
phenotypic features is highly unlikely to have occurred
by chance; nevertheless, functional studies will be
required to show conclusively that truncating mutations
in ASXL3 have pathological consequences that cause
the observed disease trait.
Although all four subjects shared clinical findings,
these characteristics were mostly non-specific. Severe
feeding difficulties, present from birth, that required
intervention (3/4 subjects). The subjects had small size
at birth (3/4), with microcephaly (3/4) and severe psy-
chomotor delay, with missed milestones (4/4) at their
most recent evaluation. Deep palmar creases (4/4) and
slight ulnar deviation of the hands (3/4), combined with
a high arched palate (3/4) were also common. No
patient had the typical ‘BOS posture’ of elbow and wrist
flexion, or of myopia or trigonocephaly (0/4).
The phenotype present in the three affected individuals
varies in both presentation and severity, a phenomenon
that is also reported in subjects with ASXL1 mutation.
Several factors may account for this. First, truncating
mutations occurring earlier in the gene seem to be asso-
ciated with a more severe phenotype, with truncating
mutations at the extreme 3’ end of the gene yielding no
observed phenotype. Interestingly, this does not seem to
be the case for ASXL1 [2]. Additional subjects will be
needed for further genotype-phenotype analysis to address
a potential polarity hypothesis [23]. Second, because of the
importance of the ASXL gene family in very early develop-
ment, the time at which the mutation arose may also influ-
ence the phenotypic outcome; mutations that occurred in
the parental gametes could convey a more severe pheno-
type than those arising post-zygotically or during later
embryogenesis [24]. Third, ASXL proteins form complexes
with other proteins, and have been shown to influence Trx
gene mutations in flies [12]. Mutational load and other
epistatic effects may contribute to the observed phenotype,
and we could not discern such alleles using our de novo
variant approach. Finally, epigenetic factors may contri-
bute to the phenotype. In mice, homozygous Asxl2 muta-
tions can lead to two primary outcomes: around 20% are
born very small and die by the age of 2 months, whereas
the remaining 80% are smaller at birth but gain weight
normally and are successfully weaned [25]. Thus, other
factors may contribute to the penetrance and/or expressiv-
ity of de novo ASXL3 mutations in humans, and severe
phenotypes could be atypical.
The condition defined molecularly in the current study is
phenotypically distinct from, but with similar and overlap-
ping features to BOS. This is probably the consequence of
functional overlap between the causative candidate genes
ASXL1 and ASXL3, which are both developmentally impor-
tant putative polycomb genes. Differentiating two phenoty-
pically similar syndromes based on clinical presentation
alone is challenging, and is further complicated by pheno-
typic variability. Molecular methods permit an objective
means to establish and secure a diagnosis. Moreover, these
methods now enable comparative analyses between novel
and well-described syndromes to make use of evolutionary
genetics in addition to phenotypic features in disease
nosology. This allows a distinct molecular diagnosis, and
increases diagnostic capabilities for rare syndromes. Inter-
estingly, in this study, the subjects were identified not by
establishing phenotypic overlap between them, but rather
by identifying that they shared de novo nonsense mutations
in the identical genes, and that mutations in a related gene,
ASXL1, resulted in a similar phenotype. In particular, sub-
jects 3 and 4 were identified from a small clinical cohort
(n = 192) of individuals with psychomotor delay, based
upon the presence of rare truncating ASXL3 mutations,
which were later determined to be de novo. This is a novel
way in which molecular diagnostics can help foster interna-
tional and inter-institutional collaborations that will be
vital to both solving the multitude of very rare diseases and
to functionally annotating the human genome.
Conclusion
De novo truncating ASXL3 mutations are very likely the
cause of a novel syndrome. The ability to communicate
and share genotype findings can elucidate novel disor-
ders that would be challenging to discover based on
phenotypic data alone.
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